Rashidian et al. demonstrated that a different CD8+ T cell distribution in TME (homogenous or heterogeneous) can distinguish between responding and non-responding tumors both in melanoma tumor bearing mice treated CTLA-4 therapy [107], and in colorectal adenocarcinoma mouse model treated with anti PD-1 therapy [108]. The gene discussed is CD8A; the disease is melanoma.